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Background: Conﬂicting evidence exists on whether smoking acts as an effect modiﬁer of the association
between APOE genotype and risk of coronary heart disease (CHD).
Methods and results: We searched PubMed and EMBASE to June 11, 2013 for published studies reporting
APOE genotype, smoking status and CHD events and added unpublished data from population cohorts.
We tested for presence of effect modiﬁcation by smoking status in the relationship between APOE ge-
notype and risk of CHD using likelihood ratio test.
In total 13 studies (including unpublished data from eight cohorts) with 10,134 CHD events in 130,004
individuals of European descent were identiﬁed. The odds ratio (OR) for CHD risk from APOE genotype
(ε4 carriers versus non-carriers) was 1.06 (95% conﬁdence interval (CI): 1.01, 1.12) and for smoking
(present vs. past/never smokers) was OR 2.05 (95%CI: 1.95, 2.14). When the association between APOE
genotype and CHD was stratiﬁed by smoking status, compared to non-ε4 carriers, ε4 carriers had an OR
of 1.11 (95%CI: 1.02, 1.21) in 28,789 present smokers and an OR of 1.04 (95%CI 0.98, 1.10) in 101,215
previous/never smokers, with no evidence of effect modiﬁcation (P-value for heterogeneity ¼ 0.19).
Analysis of pack years in individual participant data of >60,000 with adjustment for cardiovascular traits
also failed to identify evidence of effect modiﬁcation.ision of Transplantation, Perelman School of Medicine, University of Pennsylvania, 2300 Spruce Street, Philadelphia, PA
es).
r Ireland Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
M.V. Holmes et al. / Atherosclerosis 237 (2014) 5e126Conclusions: In the largest analysis to date, we identiﬁed no evidence for effect modiﬁcation by smoking
status in the association between APOE genotype and risk of CHD.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).1. Introduction
Cardiovascular diseases are the leading cause of death world-
wide. Over recent decades, much research attention has focussed
on investigating the genetic causes of coronary heart disease (CHD).
Despite enormous advances in our understanding of the genetic
basis, it is humbling that exposure to tobacco smoke remains a
critically important, major, preventable cause of CHD [1].
One of the most widely studied genetic variants in CHD is APOE,
variation in which encodes the three common isoforms of apoli-
poprotein E (apoE), ε2, ε3, and ε4, that have important roles in
plasma lipid metabolism and transportation [2,3]. APOE variants
have a strong and consistent effect on the concentration of plasma
lipids and on risk of CHD [4]. ApoE regulates multiple additional
metabolic pathways and inﬂuences oxidative stress [5]. Previous
studies have investigated the potential role of smoking as an effect
modiﬁer of the association between genotype and CHD risk [6e8].
Early studies identiﬁed that the association between carriers of the
ε4 allele and CHD was greater amongst smokers than non-smokers
[6] but this was not replicated in larger studies [7]. However, more
recent studies that reported ﬁndings in support of effect modiﬁ-
cation have brought into question the underlying relationship [8,9].
Effect modiﬁcation is biologically plausible as in vitro studies
show that recombinant ApoE ε4 is a poorer anti-oxidant than both
ApoE ε2 and ε3 [10], and we previously reported that APOE ε4
carriers who smoked had lower anti-oxidant status [6]. Thus it is
possible that in the presence of smoking, an impaired anti-oxidant
diathesis would result in a greater risk of CHD. If true, the increase
in CHD risk caused by smoking should be greater in individuals who
carry the ε4 allele compared to individuals who do not carry the ε4
allele. However, an important argument against the plausibility of
an anti-oxidant mediated APOE-by-smoking interaction is the fact
that to date, no randomized trial of an anti-oxidant intervention has
shown a reduction in the risk of CHD, which undermines the
“oxidation hypothesis” of CHD [11].
It is therefore timely to conduct a large scale, rigorous investi-
gation to address this question. To this end, we conducted a sys-
tematic review to identify studies reporting effect modiﬁcation of
APOE genotype on risk of CHD by smoking status and supplemented
studies that met our inclusion criteria with de novo data from large
population cohorts. Concern has been raised that the scientiﬁc evi-
dence may be interpreted as suggesting that the sequelae of smok-
ing could be less serious in individuals that did not carry the APOE ε4
allele [7]. The devastating consequences of smoking to human
health is unquestionable, and the purpose of this scientiﬁc investi-
gation was not to investigate the potential protection of smoking by
certain variants of APOE genotype, but rather to investigate the po-
tential for effect modiﬁcation as a means of understanding the
biological processes by which APOE increases the risk of CHD.2. Methods
2.1. Literature search
We used the PRIMSA statement [12] as a guide and include a
completed PRISMA checklist (Supplementary table S1) and ﬂowdiagram (Supplementary ﬁgure 1). An early analysis plan is
included in the Supplementary material.
We searched PubMed and EMBASE from inception to June 11,
2013 for studies that included the keywords “APOE”, “genotype”,
“smoking” and “CHD”. Full details of the search strategy are pro-
vided in the Supplementary material. Eligible studies reported CHD
outcomes in relation to APOE genotype stratiﬁed by smoking status
in individuals of European descent. The search was conducted by
DM and a random subset of articles was double-checked by MVH.
Discrepancies were resolved by consensus. We only included
studies that reported the CHD outcome of myocardial infarction
(MI) alone or in combination with angina or cardiac interventions
(such as revascularization), thus studies reporting stroke or a
composite of CHD and stroke were excluded. Furthermore, studies
that reported angiographically-determined coronary artery steno-
sis but not clinical events were also excluded. To minimize human
error, DM and MVH conducted data entry separately and checked
for concordance between retrieved data.
We updated one previously reported study (NPHSII [6]) for CHD
events and supplemented the retrieved articles from the search
with eight additional studies: one randomized trial (Thrombosis
Prevention Trial [13]), one nested caseecontrol study (EPIC-
Netherlands [14]), one cohort (ELSA [15]) and ﬁve general popu-
lation cohorts: Copenhagen City Heart Study (CCHS) [16], Copen-
hagen General Population Study (CGPS) [17], Czech post-MONICA
[18], EPIC-Norfolk [19] and HAPIEE-Czech [20]. Ethics Committees
at the contributing centres approved use of new data for updated
and unpublished studies.
For all studies, we tested the Hardy Weinberg Equilibrium for
the genotypes determined by the two single nucleotide poly-
morphisms that encode the APOE isoforms. For published studies,
we noted whether the original report stated presence of effect
modiﬁcation in the APOEeCHD relationship by smoking status.2.2. Outcome classiﬁcation
For the new cohorts (CCHS, CGPS, Czech post-MONICA, EPIC-
Netherlands, HAPIEE-Czech), we used ICD codes speciﬁc for
myocardial infarction (i.e. ICD-8: 410, ICD-9: 410, ICD-10: I21 and
ICD-10: I22). For TPT, we used the primary outcome reported in the
original randomized trial. Outcome deﬁnitions for all studies
including those identiﬁed from the electronic search and new
studies are reported in Table 1.2.3. APOE genotype grouping
We conducted two separate genetic analyses: one simple, and
one detailed. For the simple analysis, we stratiﬁed individuals into
two groups, based on carriage of the ε4 allele of APOE genotype: ε4
carriers consisted of APOE genotypes ε3/ε4 or ε4/ε4; non-ε4 carriers
consisted of APOE genotypes ε3/ε3, ε2/ε3 or ε2/ε2. Where possible,
ε2/ε4 carriers were excluded by convention [6,21].
For the detailed genetic analysis, we used the original APOE
genotype groups and placed them into order according to the
previously reported association with CHD [4] (i.e. from lowest to
highest CHD risk: ε2/ε2, ε2/ε3, ε3/ε3, ε3/ε4 or ε4/ε4). Treating APOE
M.V. Holmes et al. / Atherosclerosis 237 (2014) 5e12 7genotype in this fashion yields a monotonic relationship between
genotype group and risk of CHD [4].
2.4. Analysis
2.4.1. Smoking status: present versus past/never
Using tabulated data, we reconstructed the original data sets
with the following variables: APOE genotype, smoking status
(present, past or never) and CHD status. This enabled us to conduct
“quasi-individual participant data” analyses to investigate the as-
sociation between APOE genotype and CHD risk. The NPHSII study
was stratiﬁed as previous studies have shown heterogeneity ac-
cording to recruitment centre [22]. For the analyses described
below, we used logistic regression with CHD status as the depen-
dent variable; the principle summary measure was therefore an
odds ratio (OR). In every analysis, we adjusted for study design
using an unordered categorical variable with the “i.” preﬁx in Stata.
For the simple analysis, we initially tested the univariate asso-
ciation between smoking and APOE ε4 genotype carrier status
(comparing ε4 carriers to non-carriers) individually with CHD,
which served to validate our data set for the analysis of effect
modiﬁcation. Second, we stratiﬁed the association between APOE
genotype and CHD by smoking status (into present vs. previous/
never; this groupingwas used as it was themost widely-reported in
the identiﬁed studies and allowed us to include all studies). Finally,
we tested for an interaction between APOE and smoking by ﬁtting
two statistical models: (i) a multivariate model with CHD status as
the dependent variable, and smoking status and APOE genotype as
the independent variables (adjusting for study design), and (ii) a
model consisting of the same variables as model (i), but with an
interaction term ﬁtted between smoking status and APOE genotype.
We used the Likelihood ratio test (LRT) to test the null hypothesis
that the simpler model lacking the interaction term, i.e. model (i),
explained the data better. We used a generous P-value threshold
(<0.05) from the LRT as evidence against the null hypothesis (of no
effect modiﬁcation). To investigate whether there was a relation-
ship between sample size and evidence for effect modiﬁcation, we
also conducted the LRT for effect modiﬁcation between APOE ge-
notype and smoking status in each study individually, and plotted
the P-values derived from LRT against sample size, grouped by
whether the original publication reported evidence of effect
modiﬁcation. We tested for evidence of a pair-wise correlation be-
tween sample size and LRT P-value by obtaining the Pearson’s
correlation coefﬁcient from the “pwcorr” command in Stata.
In the detailed genetic analysis, we investigated the association
between APOE genotype with odds of CHD in the three large pop-
ulation cohorts (EPIC-Norfolk, CCHS and CGPS) in which outcomes
were ICD codes for myocardial infarction, with detailed information
on smoking (present, past, never) and APOE genotype. We arranged
genotype groups in order according to the reported association
with CHD risk in the largest genetic association reported to date [4].
Thus, individuals were assigned a numerical value of 1e5
depending on their APOE genotype (1 ¼ ε2/ε2, 2 ¼ ε2/ε3, 3 ¼ ε3/ε3,
4 ¼ ε3/ε4 or 5 ¼ ε4/ε4). In all individuals (irrespective of smoking
status), we ﬁrst obtained the odds ratio of CHD for each individual
group by conducting a categorical logistic regression analysis, using
the ε3/ε3 genotype as the reference group. We then tested for the
presence of a linear association between the APOE genotype groups
using logistic regression, by treating the APOE genotype as a
continuous trait (thus the beta coefﬁcient on the log odds scale for
this trait was the slope for an incremental increase in APOE geno-
type). Next, we stratiﬁed the analysis by smoking status into pre-
sent, past or never and reconstructed the plots. For each of these
three smoking groups, we generated a slope for the association
between APOE genotype and log odds of CHD. Finally, we tested fora difference in these three slopes (of the linear estimates for APOE
genotype by smoking status: present, past, never smoking) by
ﬁtting an interaction term between APOE genotype status and
smoking status in the logistic regression model and using likeli-
hood ratio test to investigate whether a simpler model (without the
interaction term ﬁtted) better explained the data.
2.4.2. Pack years and adjustment for other cardiovascular risk
factors
In addition to the analysis of present vs. past/never smoker in all
studies (including published and unpublished data), access to in-
dividual participant data in two large population-based studies
(Copenhagen General Population Study and Copenhagen City Heart
Study) with a pooled sample size of 68,177 facilitated the conduct of
a more detailed analysis of smoking phenotype and permitted
statistical adjustment for cardiovascular risk factors.
For this, we used pack years, a trait that encompasses both the
number of cigarettes smoked per day and the duration of smoking
(one pack year is equivalent to 20 cigarettes smoked every day for
one year). We conducted logistic regression analyses using pack
years as a categorical variable. In detail, the dependent variable was
MI, and the independent variables were pack years (treated as an
unordered categorical variable with individuals grouped into 0, >0
to <10, 10 to <20 and 20 pack years), and APOE ε4 genotype
carrier status (dichotomized into ε4 carriers and non-carriers). This
was conducted initially in the two studies separately, unadjusted for
any other traits. The model was then repeated with an interaction
term ﬁtted between pack years and APOE genotype status and the
Likelihood ratio test was used to test model ﬁt. We then repeated
these analyses with statistical adjustment for the following car-
diovascular traits (that could act as confounders): (i) age (grouped
into 10-year blocks), (ii) gender, (iii) hypertension (classiﬁed as SBP
140 mmHg or DBP >90 mmHg) and (iv) type 2 diabetes (T2D,
ascertained from the following ICD codes: ICD-8: 250; ICD-10: E11,
E13 and E14) to investigate whether an interaction between pack
years and APOE genotype emerged. Finally, a fully adjusted model
was ﬁtted that included all cardiovascular variables.
All analyses were conducted using Stata version 13.1 (StataCorp,
College Station, Texas 77845 USA).
3. Results
Of the 425 articles retrieved from the search, ﬁve studies met
our inclusion criteria (Supplementary ﬁgure 1) [6,7,9,23,24]. To this,
we updated data from one cohort and added data from eight new
studies (Supplementary ﬁgure 1). This yielded a total of 13 studies
with 10,134 CHD events in 130,004 individuals of European descent
of whom 28,789 were present smokers.
Study characteristics including age and gender are provided in
Table 1. Twenty-two per cent of individuals in the pooled data set
were current smokers and 28% were carriers of the APOE ε4 allele
(study-level characteristics are reported in Supplementary
Table S2). The genotypes of the SNPs comprising the APOE iso-
forms were in Hardy Weinberg Equilibrium in all contributing
studies. Two of the ﬁve previously published studies reported ev-
idence of effect modiﬁcation of the association between APOE ge-
notype and CHD risk by smoking status [6,9]. In these two studies,
the outcomes were a composite that included angina, silent MI or
coronary artery surgery.
3.1. Univariate association of APOE genotype and smoking status
with CHD
Carriers of the ε4 allele had an OR of CHD of 1.06 (95%CI 1.01,
1.12; P ¼ 0.01) compared to individuals who did not carry the ε4
Table 1
Characteristics of the studies included in the analysis.
Ref/study Study design Country
of origin
Number
of study
participant
Age, mean (SD)
(controls in
caseecontrol
studies)
Proportion
male, %
(controls in
case-control
studies)
Recruitment Follow-up
(years)
CHD outcomes Outcome ascertainment APOE
SNPs in
HWE?
Original
report stated
presence of
effect
modiﬁcation?a
Published studies identiﬁed in the systematic review
Gustavsson et al.
[9]/INTERGENE
and SHEEP
Caseecontrol Sweden 6389 54 (12) 46.2 Cases were patients with
ﬁrst or recurrent CHD
and controls were
randomly selected
from the population
N/A Acute MI,
unstable
angina, CHD
exacerbations
MI: changes in blood
levels of
the enzymes CK and LDH,
speciﬁed ECG-changes
and autopsy ﬁndings
according to the Swedish
Association of
Cardiologists in 1991
Yes Yes
Keavney
et al. [7]/ISIS
Caseecontrol UK 7385 46 (10) 67.9 Cases were patients with
suspected AMI and controls
selected from the relatives
and spouses of the case
group
N/A Acute MI Cardiac enzyme or
electrocardiographic
criteria, or both
Yes No
Liu et al.
[23]/Physicians'
Health Study
Nested
caseecontrol
USA 731 60 (9) 100 Male physicians registered
with the American Medical
Association
12 Fatal and
nonfatal MI
WHO criteria for MI.
Autopsies and deaths
recorded for fatal
MI diagnoses.
Yes No
Talmud et al.
[24]/Whitehall II
Prospective
cohort
UK 5380 57 (6) 100 Randomly selected among
British civil servants
5.8 Fatal/nonfatal MI,
angina (deﬁnitive
or probable)
Fatal MI: national
registries; nonfatal
MI: MONICA criteria;
angina: abnormal
investigation such
as angiography, exercise
electrocardiography,
stress imaging, study
electrocardiogram
or clinical conﬁrmation
Yes No
Published studies identiﬁed in the systematic review updated for incident CHD events
Humphries
et al. [6]/NPHSII
Prospective
cohort
UK 2630 55.7 (3.2) 100 General practices, hospital
clinics, coroner's ofﬁces
>10 Fatal CHD
(coronary
deaths/fatal MI),
nonfatal MI,
coronary artery
surgery and
silent MI
WHO criteria Yes Yes
Studies not previously published
Copenhagen
City Heart Study
(CCHS)
Prospective
cohort
Denmark 8926 55.1(15.1) 44 Population-based 34 Fatal and
nonfatal MI
ICD-8: 410; ICD-10: I21 and I22 Yes N/A
Copenhagen General
Population
Study (CGPS)
Prospective
cohort
Denmark 57,942 57.1(13.3) 44 Population-based 34 Fatal and
nonfatal MI
ICD-8: 410; ICD-10: I21 and I22 Yes N/A
Czech post-MONICA Prospective
cohort
Czech
Republic
1875 55.0 (10.3) 45 Population-based 6 Nonfatal MI ICD-10: I21 and I22 Yes N/A
ELSA Cohort UK 5020 67.5 (9.8) 46 Respondents of
Nationwide survey
11 Fatal and
nonfatal CHD
Fatal CHD (ICD-10: I20eI25)
and self-reported CHD
Yes N/A
EPIC-Netherlands Nested
caseecontrol
Netherlands 2129 54.1 (10.1) 22 Population-based 13 Fatal and
nonfatal MI
ICD-9: 410; ICD-10: I21, I22 Yes N/A
EPIC-Norfolk UK 22,838 59.2 (9.2) 46 Population-based 10 ICD-10: I21 and I22 Yes N/A
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M.V. Holmes et al. / Atherosclerosis 237 (2014) 5e12 9allele. Individuals who currently smoked had an OR of CHD of 2.05
(95%CI: 1.95, 2.14; P ¼ 9.7  10196) compared to individuals that
did not currently smoke (including previous or never smokers).
3.1.1. Association of APOE ε4 allele genotype with CHD stratiﬁed by
smoking status and test for interaction
In analysis of 6148 CHD cases in 101,215 individuals who did not
currently smoke, carriers of the ε4 allele had an OR of CHD of 1.04
(95%CI 0.98, 1.10; P ¼ 0.25) compared to individuals who did not
carry the ε4 allele. In 28,789 current smokers with 3986 CHD
events, carriers of the ε4 allele had an OR of CHD of 1.11 (95%CI 1.02,
1.21; P ¼ 0.02) compared to individuals who did not carry the ε4
allele.
When tested formally using likelihood ratio test, we identiﬁed
no evidence of an interaction between APOE genotype and smoking
(Parameter estimate ¼ 0.07; 95%CI: 0.03, 0.17; c2 1.72; (df ¼ 1);
P ¼ 0.19) (Fig. 1).
An investigation into the relationship between sample size and
P-value for effect modiﬁcation in each study, categorized according
to whether the original publication reported presence of effect
modiﬁcation, did not identify a relationship between sample size
and P-value for LRT (Pearson's r ¼ 0.45; P-value for
correlation ¼ 0.13). Interestingly, using our analytical approach, we
did not reproduce the small P-values for effect modiﬁcation in
either of the two previously reported studies, both of which had
fewer than 7000 participants. In contrast, the largest study in our
analysis, with a sample size of 57,942 (and which used ICD codes
speciﬁc for MI), had the largest P-value for interaction (P ¼ 0.96;
Fig. 2).
3.2. Detailed analysis
When we investigated the association between APOE genotype
status and CHD regardless of smoking status, we found strong ev-
idence for a linear association between APOE genotype and CHD
status when individuals were arranged in the following order: ε2/
ε2, ε2/ε3, ε3/ε3, ε3/ε4 or ε4/ε4 with the log odds of CHD increasing
by 0.046 (SE 0.019; P¼ 0.017) for each incremental increase in APOE
genotype status (Fig. 3).
When we stratiﬁed this analysis by smoking status into three
groups (present, past or never smokers), and tested for evidence of
heterogeneity in the association between APOE genotype and odds
of CHD according to smoking status, we found no evidence to
support effect modiﬁcation (P for heterogeneity of slopes by
smoking status ¼ 0.35; Fig. 3 and Supplementary Table S3).
3.2.1. Analysis of pack years in two large prospective cohorts with
MI outcomes
In 59,349 and 8828 individuals in CGPS and CCHS, respectively,
when an interaction term was ﬁtted between APOE genotype (ε4
allele carriers vs. non-carriers) and pack years, no evidence for an
interaction for risk of MI was identiﬁed (P-values for
interaction ¼ 0.54 and 0.65 for CGPS and CCHS, respectively)
(Supplementary Tables S4 and S5). This ﬁnding did not alter with
subsequent adjustment for age, gender, hypertension or T2D
(Supplementary Tables S6 and S7).
4. Discussion
This study represents the largest investigation to date into the
role of smoking in the association between APOE genotype status
and risk of CHD. We conducted a systematic review and supple-
mented identiﬁed studies with unpublished and updated data, and
found that the association between APOE genotype and CHD was
not meaningfully different when stratiﬁed by smoking status. Our
Fig. 1. Association between APOE genotype and CHD in all individuals and stratiﬁed by smoking status. P-value for heterogeneity obtained from testing whether an interaction term
between APOE and smoking represents the data better than no interaction term (tested using likelihood ratio test).
M.V. Holmes et al. / Atherosclerosis 237 (2014) 5e1210interpretation is that there is no evidence to support the hypothesis
that smoking is an effect modiﬁer of the association between APOE
genotype and CHD events.
In clinical trials, the standard method of testing effect modiﬁ-
cation is to perform analyses stratiﬁed by the potential modiﬁer
[25], and investigate for differences between the treatment effects
amongst strata. Owing to the random allocation of alleles at
gametogenesis, genetic studies share many of the features of ran-
domized trials [26], thus a similar strategy can be used for inves-
tigating geneeenvironment interactions. This can be conducted by
comparing summary estimates frommeta-analysis stratiﬁed by the
potential effect modiﬁer, or by re-constructing individual partici-
pant data (from summary tabulated data, as we did in this analysis)
and conducting a likelihood ratio test with and without an inter-
action term ﬁtted between the exposure (in this case APOE geno-
type) and potential modiﬁer (smoking status). A large P-value on
likelihood ratio test (as identiﬁed in our analysis) makes the pres-
ence of effect modiﬁcation unlikely.
This study adds to the growing list of examples of initial reports
of effect modiﬁcation in individual small studies that were subse-
quently refuted by large-scale evidence [27], a form of “winner'sFig. 2. Scatter plot of the P-value for interaction and sample size in the 13 studies. P-
value obtained from testing whether an interaction term between APOE and smoking
represents the data better than no interaction term (tested using likelihood ratio test).
The correlation between P-value and sample size was Pearson's r ¼ 0.45 (P-value for
correlation ¼ 0.13).curse” [28]. Spurious effect modiﬁcation is a concern when sample
sizes are small [29]. In our analysis, we had over 10,000 CHD cases
in over 130,000 individuals, meaning that the absence of evidence
for heterogeneity in the estimates of APOE genotype with odds of
CHD when stratiﬁed by smoking status indicates that a clinically
relevant difference between smoking subgroups is very unlikely.
Although it is tempting to interpret the estimate for CHD seen in
non-smoking ε4 carriers as suggestive that this subgroup does not
have an elevated risk of CHD compared to non-ε4 carriers (since the
95%CI includes the null), this is likely due to reduced power within
strata of subgroups, and the salient feature is the lack of evidence
for interaction between APOE genotype and smoking status.
It is curious that we did not replicate the presence of effect
modiﬁcation for two previous studies included in our analysis. This
could be accounted for by updating one study (NPHSII) [6] for
incident CHD events and in the other [9], effect modiﬁcation was
stronger in women than men. Furthermore, lack of access to indi-
vidual participant data, and alternative analytical strategies in
previous studies such as use of never smokers as the baseline group
and comparing present and past smokers stratiﬁed by APOE ge-
notype to this baseline, could also account for the discrepancy. It is
noteworthy that both individual studies were relatively small and
that the largest single study in this analysis (with a sample size over
6-fold greater than the combined sample size of the two previous
studies with presence of effect modiﬁcation) had the largest P-
value for interaction.
There are several limitations to this study. Firstly, although we
conducted a “quasi-individual participant data” analysis, we did not
have access to individual participant data for all included studies,
and thereforewere not able to conduct multivariate analyses taking
into account potential confounders such as age, gender and social
status. However, we were able to conduct a detailed analysis in the
large data sets that we had access to individual data. Second, we did
not have markers of oxidative stress that we could use for a more
detailed investigation into oxidative pathways as potential medi-
ators of the association between APOE genotype and risk of CHD.
Our study also has several advantages. First, this is the largest
analysis to date, incorporating new data from three very large
prospective cohorts and ﬁve other studies. Second, using the data
sets with reﬁned data on APOE genotype status and in which
outcome ascertainment was conducted using ICD codes to make
our outcome speciﬁc to myocardial infarction, we were able to
conduct a more detailed analysis by investigating evidence for a
Fig. 3. Detailed association between APOE genotype and CHD overall (left) and stratiﬁed by smoking status (right).
M.V. Holmes et al. / Atherosclerosis 237 (2014) 5e12 11difference in the slope of the APOEeCHD relationship by smoking
status. Third, we were able to examine a more detailed smoking
phenotype (pack years) in two large prospective cohorts with a
combined sample size of 68,177. Both the simple and detailed ge-
netic and smoking analyses failed to identify evidence to support
the hypothesis that smoking status acts as an effect modiﬁer of the
relationship between APOE genotype with CHD risk.
In conclusion, in the largest analysis to date including new data
from large population-based cohorts, we identiﬁed no evidence to
support the hypothesis that smoking status modiﬁes the associa-
tion between APOE genotype and risk of CHD. Regardless of these
ﬁndings, as the leading cause of preventable disease and death in
the world, smoking should be actively discouraged in all
individuals.
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